Go to content
UR Home

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Hehlmann, R. ; Lauseker, M. ; Saußele, S. ; Pfirrmann, M. ; Krause, S. ; Kolb, H. J. ; Neubauer, A. ; Hossfeld, D. K. ; Nerl, C. ; Gratwohl, A. ; Baerlocher, G. M. ; Heim, D. ; Brümmendorf, T. H. ; Fabarius, A. ; Haferlach, C. ; Schlegelberger, B. ; Müller, M. C. ; Jeromin, S. ; Proetel, U. ; Kohlbrenner, K. ; Voskanyan, A. ; Rinaldetti, S. ; Seifarth, W. ; Spieß, B. ; Balleisen, L. ; Goebeler, M. C. ; Hänel, M. ; Ho, A. ; Dengler, J. ; Falge, C. ; Kanz, L. ; Kremers, S. ; Burchert, A. ; Kneba, M. ; Stegelmann, F. ; Köhne, C. A. ; Lindemann, H. W. ; Waller, C. F. ; Pfreundschuh, M. ; Spiekermann, K. ; Berdel, W. E. ; Müller, L. ; Edinger, M. ; Mayer, J. ; Beelen, D. W. ; Bentz, M. ; Link, H. ; Hertenstein, B. ; Fuchs, R. ; Wernli, M. ; Schlegel, F. ; Schlag, R. ; de Wit, M. ; Trümper, L. ; Hebart, H. ; Hahn, M. ; Thomalla, J. ; Scheid, C. ; Schafhausen, P. ; Verbeek, W. ; Eckart, M. J. ; Gassmann, W. ; Pezzutto, A. ; Schenk, M. ; Brossart, P. ; Geer, T. ; Bildat, S. ; Schäfer, E. ; Hochhaus, A. ; Hasford, J.



Abstract

Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n = 400) could be optimized by doubling the dose (n = 420), adding interferon (IFN) (n = 430) or cytarabine (n = 158) or using IM after IFN-failure (n = 128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: daten@ur.de
0941 943 -5707

Contact persons